Previous 10 | Next 10 |
Significantly elevated baseline C5a levels occur in hidradenitis suppurativa (HS) patients Vilobelimab dose-dependently suppresses C5a levels over time accompanied by the previously reported reduction in inflammatory lesion counts and scores Data support continued development of v...
The following slide deck was published by InflaRx N.V. in conjunction with this event. For further details see: Inflarx (IFRX) Presents at J.P. Morgan Healthcare Conference 2021 - Slideshow
Gainers: Organogenesis Holdings (ORGO) +33%. Lexicon Pharmaceuticals (LXRX) +30%. NantKwest (NK) +27%. Oragenics (OGEN) +25%. Bicycle Therapeutics (BCYC) +23%.Losers: Viveve Medical (VIVE) -23%. Cassava Sciences (SAVA) -12%. Timber Pharmaceuticals (TMBR) -11%. InflaRx N.V. (IFRX) -9...
Multiple data readouts expected in 2021 Phase II trial in patients with cutaneous squamous cell carcinoma expected to start in the first half of 2021 JENA, Germany, Jan. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing an...
JENA, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference being held ...
InflaRx ([[IFRX]] +2.5%) has completed enrollment in the European Phase 2 IXCHANGE study of vilobelimab (IFX-1), in ANCA-associated vasculitis ((AAV)), a group disorders characterized by destruction and inflammation of small vessels.The 57-subject study's main objective is to evaluate the saf...
JENA, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the European phase II IXCHANGE study of vilobelimab (IFX-1), a first-in-class ant...
InflaRx (IFRX): Q3 GAAP EPS of -€0.25.Cash, equivalents and financial assets of ~€95.7M.Press Release For further details see: InflaRx reports Q3 results
Initiated Phase III part of the Phase II/III adaptive, randomized, controlled trial in patients with severe COVID-19 induced pneumonia Published encouraging data from Phase II part of COVID-19 trial in The Lancet Rheumatology Announced leadership team additions Cash, cash equi...
4 Penny Stocks To Watch Right Now Whether you’re a beginning investor or a seasoned professional, penny stocks have a lot to offer. To start, penny stocks are simply any that trade below the $5 mark. With this broad categorization, there are plenty of penny stocks to wa...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...